Carmell Therapeutics Corporation Cash Flow-to-Debt Ratio
Carmell Therapeutics Corporation cash flow-to-debt ratio. Carmell Therapeutics Corporation (CTCX) has a Cash Flow-to-Debt Ratio of -0.11x as of March 2025, meaning its operating cash flow of $-752.95K could theoretically repay 0% of its total liabilities ($7.14 Million) in one year. Check CTCX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Carmell Therapeutics Corporation (2021–2024)
Cash flow-to-debt ratio of Carmell Therapeutics Corporation from 2021 to 2024. Historical debt coverage capacity for Carmell Therapeutics Corporation across 4 annual periods. Also explore Carmell Therapeutics Corporation net asset momentum to track the company's year-over-year net asset growth rate.
Carmell Therapeutics Corporation Cash Flow-to-Debt Ratio by Year (2021–2024)
Carmell Therapeutics Corporation cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for Carmell Therapeutics Corporation. For the full cash flow conversion analysis, see CTCX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.71x | $-4.39 Million | $6.19 Million | ▼ -233.1% |
| 2023 | -0.21x | $-8.35 Million | $39.20 Million | ▼ -145.6% |
| 2022 | -0.09x | $-3.43 Million | $39.54 Million | ▼ -129.4% |
| 2021 | -0.04x | $-1.18 Million | $31.13 Million | — |